Irina Honin

Irina Honin

Auto-generated profile, based on publicly available information

Irina Honin

University of Bonn

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SZShiyang Zhai
Shiyang Zhai
IHIrina Honin
Irina Honin
LSLinda Schäker-Hübner
Linda Schäker-Hübner
MHMaria Hanl
Maria Hanl
LJLukas Jacobi
Lukas Jacobi
FHFinn K. Hansen
Finn K. Hansen

20 May 2025 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
TSTao Sun
Tao Sun
SZShiyang Zhai
Shiyang Zhai
BKBeate König
Beate König
IHIrina Honin
Irina Honin
CKCindy-Esther Kponomaizoun
Cindy-Esther Kponomaizoun
FHFinn K. Hansen
Finn K. Hansen

5 August 2025 in ACS Pharmacology & Translational Science
Verified
Journal Article
Closed access
MHMaria Hanl
Maria Hanl
FFFelix Feller
Felix Feller
IHIrina Honin
Irina Honin
KTKathrin Tan
Kathrin Tan
MMMartina Miranda
Martina Miranda
FHFinn K. Hansen
Finn K. Hansen

14 November 2025 in ACS Pharmacology & Translational Science
Verified
Journal Article
Open access
IHIrina Honin
Irina Honin
TSTao Sun
Tao Sun
NSNisha Setia
Nisha Setia
LSLinda Schäker-Hübner
Linda Schäker-Hübner
FHFinn K. Hansen
Finn K. Hansen
Histone deacetylases (HDACs) regulate gene expression and are promising targets in oncology. Especially the class I isoforms HDAC1 and HDAC2 are overexpressed in cancer. However, while ortho-aminoanilides with a suitable (het)-aryl substitution are well-characterized HDAC1/HDAC2 inhibitors, the corresponding phenol analogs have not been sufficiently investigated so far. To this end, we compared the ortho-hydroxyanilide derivative ST13 with the pan-HDAC inhibitor vorinostat and Cpd-60, an ortho-aminoanilide with high HDAC1/HDAC2 selectivity. ST13 was further developed into a light-activatable prodrug (ST17) by masking its zinc-binding group with a photoremovable 4,5-dimethoxy-2-nitrobenzyl protecting group. Overall, we verified that ST13 is a selective, slow- and tight-binding HDAC1/HDAC2 inhibitor with antiproliferative activity. Furthermore, we demonstrated that the light-activatable prodrug ST17 readily releases ST13 upon irradiation, thereby allowing to precisely control its antiproliferative properties. These findings validate ortho-hydroxyanilides as effective HDAC1/HDAC2-selective inhibitors and highlight photocaging as a promising strategy to achieve spatiotemporal control of epigenetic therapies in cancer.

18 February 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
FFFelix Feller
Felix Feller
HWHeiko Weber
Heiko Weber
MMMartina Miranda
Martina Miranda
IHIrina Honin
Irina Honin
MHMaria Hanl
Maria Hanl
FHFinn K. Hansen
Finn K. Hansen
Proteolysis-targeting chimeras (PROTACs) have recently gained popularity as targeted protein degradation (TPD) promises to overcome the limitations of occupancy-driven pharmacology. However, most degraders rely on a small number of E3 ligases. In this study, we present the first-in-class histone deacetylase (HDAC) PROTACs recruiting the DDB1- and CUL4- associated factor 11 (DCAF11). We established a synthesis route entirely on solid-phase to prepare a set of eleven degraders. The long and flexible spacer bearing FF2039 (1j) showed significant HDAC1 and 6 degradation in combination with cytotoxicity against the multiple myeloma cell line MM.1S. Further investigations revealed that 1j was also able to degrade HDAC isoforms of class I, IIa and IIb. Compared to our previously published cereblon-recruiting HDAC6 selective PROTAC A6, we succesfully transformed the selective degrader into a pan-HDAC degrader by switching the recruited E3 ligase. A detailed profiling of the anticancer properties of 1j demonstrated its significant antiproliferative activity against both hematological and solid cancer cell lines, driven by cell cycle arrest and apoptosis induction.

12 February 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
DSDaniel Stopper
Daniel Stopper
IHIrina Honin
Irina Honin
FFFelix Feller
Felix Feller
FHFinn K. Hansen
Finn K. Hansen
Histone deacetylases (HDACs) are promising targets for epigenetic drug discovery. Additionally, targeted degradation of HDACs has emerged as a novel approach in medicinal chemistry and chemical biology. However, most inhibitors and degraders rely on the potentially genotoxic hydroxamate as a zinc-binding group (ZBG). In this study, we present the development of HDAC6-directed proteolysis-targeting chimeras (PROTACs) featuring an ethyl hydrazide moiety as an alternative ZBG. This approach avoids the genotoxicity concerns of hydroxamates while maintaining potent HDAC6 degradation. We synthesized a series of CRBN- and VHL-recruiting PROTACs and identified several potent HDAC6 degraders (HDAC6 Dmax > 80%). Among these, 17c was the most effective, achieving an HDAC6 degradation of 91% and a DC50 value of 14 nM. Further characterization proved that 17c acts via the ubiquitin-proteasome system and chemoproteomics confirmed selective HDAC6 degradation over other HDAC isoforms.